Pharmaxis Ltd operates in the Commercial physical research sector. Pharmaxis Ltd (Pharmaxis) is an Australia-based company engaged in the research, development and commercialization of human healthcare products for the treatment and management of respiratory diseases. The Company is most advanced in the development of products for asthma, cystic fibrosis and bronchiectasis. The Company's product, Aridol is an airways inflammation test administered as a dry powder in a hand held inhaler where doctors can use the results of the test to identify airway hyper-responsiveness which is an attribute of asthma. It has developed Bronchitol product for the management of chronic obstructive lung diseases, including cystic fibrosis, bronchiectasis and chronic bronchitis. Bronchitol is a formulation of mannitol administered as a dry powder in a convenient hand-held inhaler. The Company's subsidiaries include Pharmaxis Pharmaceuticals Limited, Pharmaxis, Inc., Topigen Pharmaceuticals Inc. and Technology Innovation Limited. In our complete report available for purchase the company is compared to: OBJ Limited, Hexima Limited and Probiomics Limited.